Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer

Erez Shmuel Davidi; Tamar Dreifuss; Menachem Motiei; Eliezer Shai; Dimitri Bragilovski; Leon Lubimov; Marc Jose Jonathan Kindler; Aron Popovtzer; Jeremy Don; Rachela Popovtzer

doi:10.1002/hed.24935

Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer

Erez Shmuel Davidi, Tamar Dreifuss, Menachem Motiei, Eliezer Shai, Dimitri Bragilovski, Leon Lubimov, Marc Jose Jonathan Kindler, Aron Popovtzer, Jeremy Don, Rachela Popovtzer

Research output: Contribution to journal › Article › peer-review

81 Scopus citations

Abstract

Background: The purpose of this study was to develop a nanoplatform, which simultaneously acts as radiosensitizer, drug carrier, and tumor imaging agent for head and neck cancer. Methods: We synthesized 20 nm gold nanoparticles, coated with glucose and cisplatin (CG-GNPs). Their penetration into tumor cells and their cellular toxicity were evaluated in vitro. In vivo experiments were conducted to evaluate their impact on tumor growth and their imaging capabilities. Results: The CG-GNPs showed efficient penetration into tumor cells and similar cellular toxicity as cisplatin alone. Combined with radiation, CG-GNPs led to greater tumor reduction than that of radiation alone and radiation with free cisplatin. The CG-GNPs also demonstrated efficient tumor imaging capabilities. Conclusion: Our CG-GNPs have a great potential to increase antitumor effect, overcome resistance to chemotherapeutics and radiation, and allow imaging-guided therapy.

Original language	English
Pages (from-to)	70-78
Number of pages	9
Journal	Head and Neck
Volume	40
Issue number	1
Early online date	17 Nov 2017
DOIs	https://doi.org/10.1002/hed.24935
State	Published - Jan 2018

Bibliographical note

Publisher Copyright:
© 2017 Wiley Periodicals, Inc.

Funding

This work was partially supported by the Israel Cancer Research Fund (ICRF), by the Israel Science Foundation (ISF) and by the doctoral scholarship for applicable and scientific engineering research, granted to Tamar Dreifuss by the Ministry of Science and Technology, Israel. This work was partially supported by the Israel Cancer Research Fund (ICRF) and by the doctoral scholarship for applicable and scientific engineering research, granted to Tamar Dreifuss by the Ministry of Science and Technology, Israel.

Funders	Funder number
Israel Cancer Research Fund
Israel Science Foundation
Ministry of science and technology, Israel

Keywords

CT
cancer
cisplatin
gold nanoparticles
radiotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.24935

Cite this

@article{eb5dc3b9ab6849ab9f5d9b113b037799,

title = "Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer",

abstract = "Background: The purpose of this study was to develop a nanoplatform, which simultaneously acts as radiosensitizer, drug carrier, and tumor imaging agent for head and neck cancer. Methods: We synthesized 20 nm gold nanoparticles, coated with glucose and cisplatin (CG-GNPs). Their penetration into tumor cells and their cellular toxicity were evaluated in vitro. In vivo experiments were conducted to evaluate their impact on tumor growth and their imaging capabilities. Results: The CG-GNPs showed efficient penetration into tumor cells and similar cellular toxicity as cisplatin alone. Combined with radiation, CG-GNPs led to greater tumor reduction than that of radiation alone and radiation with free cisplatin. The CG-GNPs also demonstrated efficient tumor imaging capabilities. Conclusion: Our CG-GNPs have a great potential to increase antitumor effect, overcome resistance to chemotherapeutics and radiation, and allow imaging-guided therapy.",

keywords = "CT, cancer, cisplatin, gold nanoparticles, radiotherapy",

author = "Davidi, {Erez Shmuel} and Tamar Dreifuss and Menachem Motiei and Eliezer Shai and Dimitri Bragilovski and Leon Lubimov and Kindler, {Marc Jose Jonathan} and Aron Popovtzer and Jeremy Don and Rachela Popovtzer",

note = "Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2018",

month = jan,

doi = "10.1002/hed.24935",

language = "אנגלית",

volume = "40",

pages = "70--78",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer

AU - Davidi, Erez Shmuel

AU - Dreifuss, Tamar

AU - Motiei, Menachem

AU - Shai, Eliezer

AU - Bragilovski, Dimitri

AU - Lubimov, Leon

AU - Kindler, Marc Jose Jonathan

AU - Popovtzer, Aron

AU - Don, Jeremy

AU - Popovtzer, Rachela

PY - 2018/1

Y1 - 2018/1

N2 - Background: The purpose of this study was to develop a nanoplatform, which simultaneously acts as radiosensitizer, drug carrier, and tumor imaging agent for head and neck cancer. Methods: We synthesized 20 nm gold nanoparticles, coated with glucose and cisplatin (CG-GNPs). Their penetration into tumor cells and their cellular toxicity were evaluated in vitro. In vivo experiments were conducted to evaluate their impact on tumor growth and their imaging capabilities. Results: The CG-GNPs showed efficient penetration into tumor cells and similar cellular toxicity as cisplatin alone. Combined with radiation, CG-GNPs led to greater tumor reduction than that of radiation alone and radiation with free cisplatin. The CG-GNPs also demonstrated efficient tumor imaging capabilities. Conclusion: Our CG-GNPs have a great potential to increase antitumor effect, overcome resistance to chemotherapeutics and radiation, and allow imaging-guided therapy.

AB - Background: The purpose of this study was to develop a nanoplatform, which simultaneously acts as radiosensitizer, drug carrier, and tumor imaging agent for head and neck cancer. Methods: We synthesized 20 nm gold nanoparticles, coated with glucose and cisplatin (CG-GNPs). Their penetration into tumor cells and their cellular toxicity were evaluated in vitro. In vivo experiments were conducted to evaluate their impact on tumor growth and their imaging capabilities. Results: The CG-GNPs showed efficient penetration into tumor cells and similar cellular toxicity as cisplatin alone. Combined with radiation, CG-GNPs led to greater tumor reduction than that of radiation alone and radiation with free cisplatin. The CG-GNPs also demonstrated efficient tumor imaging capabilities. Conclusion: Our CG-GNPs have a great potential to increase antitumor effect, overcome resistance to chemotherapeutics and radiation, and allow imaging-guided therapy.

KW - CT

KW - cancer

KW - cisplatin

KW - gold nanoparticles

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85033573604&partnerID=8YFLogxK

U2 - 10.1002/hed.24935

DO - 10.1002/hed.24935

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 29130566

SN - 1043-3074

VL - 40

SP - 70

EP - 78

JO - Head and Neck

JF - Head and Neck

IS - 1

ER -

Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this